Grizzly Bulls
Following Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals

Financial performance and company analysis from public filings and market data.
REGNNasdaq
Regeneron Pharmaceuticals Common Stock
Latest close
$805.64
Oct 21, 2026 · completed session
Company website ↗Compare companies

Company snapshot

A consistent view of the latest supported company value and reported operating results.

Market cap
$84.33B
Shares reported Jul 23, 2026
Revenue (TTM)
$15.53B
Through Jun 30, 2026
Net income (TTM)
$4.33B
Through Jun 30, 2026
Free cash flow (TTM)
$3.76B
Through Jun 30, 2026

Fundamental lens

Four transparent questions from retained financial evidence. Each result stands on its own; Grizzly Bulls does not combine them into a score, ranking, or recommendation.

Profitability
Profitable
Is trailing-twelve-month net income positive?

Trailing-twelve-month net income is positive. As of 2026-06-30.

Net income (TTM): $4.3B
Cash generation
Positive free cash flow
Is trailing-twelve-month free cash flow positive?

Trailing-twelve-month operating cash flow less capital expenditures is positive. As of 2026-06-30.

Free cash flow (TTM): $3.8B
Liquidity
Current assets above liabilities
Do reported current assets cover reported current liabilities?

Reported current assets exceed reported current liabilities on the latest comparable retained balance sheet. As of 2026-06-30.

Current assets: $18.4B · Current liabilities: $5.5B
Recent operating direction
Unknown
What changed in the latest comparable reported results?

Comparable retained change history is not available through this reader.

How this lens works

Profitability uses only the sign of retained trailing-twelve-month net income. Cash generation uses only the sign of retained trailing-twelve-month free cash flow, defined as operating cash flow less capital expenditures.

Liquidity compares current assets with current liabilities only when both are retained for the same reporting date. It does not infer liquidity from differently dated balance sheets.

Recent operating direction uses the latest supported material financial event when comparable history exists. The existing change methodology requires at least a 10% absolute change or a sign/zero transition and compares quarterly results only with the same fiscal quarter year over year.

Descriptive decision support only. No composite score, hidden weighting, cross-company rank, or investment recommendation is produced.

Market summary

Completed-session reference prices from IEX for Oct 21, 2026.

Open
$803.30
Completed session
High
$813.55
Completed session
Low
$800.71
Completed session
Close
$805.64
Completed session

Price statistics

1M close return
0.9%
Through Oct 21, 2026
3M close return
19.3%
Through Oct 21, 2026
50-session reference-close average
$790.96
Through Oct 21, 2026

IEX historical data reflects IEX activity only and is presented as a source-scoped reference point, not as consolidated U.S. market history. Prices are unadjusted. Price returns exclude dividends and are not total returns. Historical statistics appear only when the retained source-session chain is complete and no split-like share-basis discontinuity is detected for that calculation window.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Price history

Five years of adjusted closing-price history for this listing, shown as historical context rather than a live quote.

Regeneron Pharmaceuticals five-year adjusted closing-price history1254 observations from Oct 25, 2021 to Oct 22, 2026. Values range from $479.88 to $1,190.53.$1,247.38$1,041.29$835.20$629.11$423.03Oct 25, 2021Jan 24, 2023Apr 24, 2024Jul 25, 2025Oct 22, 2026
Provider-adjusted regular-session closes · Oct 25, 2021–Oct 22, 2026 · USD per share
Market history source
About this price history

The chart uses the market provider's adjusted daily close for the current listing. It does not stitch predecessor listings and does not represent total return, benchmark performance, or historical valuation.

About the company

Regeneron is an integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases using proprietary research technologies and internal clinical and manufacturing capabilities.

Company filing ↗
Sector
Health Care
Industry
Biotechnology & Medicines
Headquarters
Tarrytown, New York, United States
Company profile reviewed from Regeneron Pharmaceuticals 2025 Form 10-K for the period ended Dec 31, 2025.
Listing & sources

Ticker: REGN · Exchange: Nasdaq · Regeneron Pharmaceuticals Common Stock

SEC issuer CIK: 0000872589